Schizophrenia – Landscape & Forecast – Disease Landscape & Forecast
The schizophrenia therapy market is crowded and dominated by atypical and typical antipsychotics. Although the continued generic erosion of oral atypical antipsychotics influences psychiatrists’ treatment decisions (e.g., the recent availability of generic lurasidone in the United States), newer oral atypical antipsychotics (e.g., Alkermes’s Lybalvi, Intra-Cellular Therapies’ Caplyta), along with drugs such as BioXcel Therapeutics’ Igalmi, are aiming to make inroads into the treatment pathway. Competition between long-acting injectables (LAIs) is also intensifying with the availability of new therapies (e.g., Janssen’s Invega Hafyera, Lundbeck / Otsuka’s Abilify Asimtufii, Teva’s Uzedy), along with the generic availability of some key LAIs. Nevertheless, novel drugs targeting key unmet needs will be welcomed (e.g., Boehringer Ingelheim’s iclepertin for cognitive impairment in schizophrenia, Acadia’s Nuplazid for the negative symptoms of schizophrenia), but other therapies in late-phase development (e.g., Karuna’s KarXT, Newron Pharmaceuticals’ evenamide) will have to clearly differentiate themselves from established therapies to gain a strong foothold in this market. As such, a deep understanding of the current and future dynamics in the schizophrenia therapy market is critical.
Questions answered
- What is the current size of the schizophrenia market in the G7 countries? What key events will influence the market over the next decade?
- What factors drive and constrain the use of newer-to-market oral and LAIs of atypical antipsychotics? How is competition heating up in these segments?
- What are the areas of highest unmet need in schizophrenia treatment? Which late-phase therapies have the potential to fulfill these needs?
- What improvements would key late-phase therapies need to demonstrate in order to compete effectively in this crowded market? How will these agents be placed in the schizophrenia treatment algorithm?
Geographies: United States, EU5, Japan
Primary research: 33 country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this and other Clarivate research
Epidemiology: Diagnosed prevalence of schizophrenia by country, segmented by positive symptoms, negative symptoms, and cognitive impairment; drug-treated prevalence of schizophrenia by country
Forecast: 10-year, annualized, drug-level sales and patient share of key schizophrenia therapies through 2032, segmented by brands/generics
Emerging therapies: Phase 3 / PR: 11 drugs; coverage of select early-phase products
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancements
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Schizophrenia - Landscape & Forecast - Disease Landscape & Forecast
- Key Updates
- October 2023
- August 2023
- May 2023
- Q4 2022
- November 2022
- October 2022
- Q3 2022
- September 2022
- Key Findings
- Schizophrenia - Key Findings - August 2023
- September 2022
- Schizophrenia - Key Findings - August 2023
- Market Outlook
- Key findings
- Market share of drug classes for schizophrenia: 2022
- Market share of drug classes for schizophrenia: 2032
- Schizophrenia SWOT analysis
- Market drivers and constraints
- What factors are driving the market for schizophrenia?
- What factors are constraining the market for schizophrenia?
- Market share and share of treated patients for schizophrenia by region: 2022 and 2032
- Major-market sales in schizophrenia by drug class: 2022-2032
- Major-market patient share by drug class and drug-treated patients in schizophrenia: 2022-2032
- Major-market brand and generic sales in schizophrenia: 2022-2032
- Major-market brand and generic patient share in schizophrenia: 2022-2032
- Drug-class-specific trends
- Major-market sales of key oral atypical antipsychotics in schizophrenia: 2022-2032
- Patient share of key oral atypical antipsychotics for schizophrenia in the United States: 2022-2032
- Patient share of key oral atypical antipsychotics for schizophrenia in the EU5: 2022-2032
- Patient share of key oral atypical antipsychotics for schizophrenia in Japan: 2022-2032
- Major-market sales of LAIs of key atypical antipsychotics in schizophrenia: 2022-2032
- Patient share of LAIs of atypical antipsychotics for schizophrenia in the United States: 2022-2032
- Patient share of LAIs of atypical antipsychotics for schizophrenia in the EU5: 2022-2032
- Patient share of LAIs of atypical antipsychotics for schizophrenia in Japan: 2022-2032
- Sales of dexmedetomidine sublingual film (Igalmi) in schizophrenia in the United States: 2022-2032
- Patient share of dexmedetomidine sublingual film (Igalmi) in schizophrenia in the United States: 2022-2032
- Sales of KarXT in schizophrenia in the United States: 2022-2032
- Patient share of KarXT in schizophrenia in the United States: 2022-2032
- Sales of iclepertin in schizophrenia by region: 2022-2032
- Patient share of iclepertin in schizophrenia by region: 2022-2032
- Sales of roluperidone in schizophrenia in the United States: 2022-2032
- Patient share of roluperidone in schizophrenia in the United States: 2022-2032
- Key findings
- Forecast
- Market Forecast Assumptions - Schizophrenia (2022-2032) - August 2023
- Market Forecast Dashboard - Schizophrenia (2022-2032) - August 2023
- Etiology and Pathophysiology
- Disease overview
- Genetic factors
- Environmental factors
- Environmental risk factors
- Biochemical risk factors for CIAS
- Biochemical factors
- Key pathways and drug targets
- Abnormalities in brain structure and function
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition, methods, and sources used
- Diagnosed lifetime prevalent cases of schizophrenia: 2022-2032
- Disease definition, methods, and sources used
- Positive symptom cases of schizophrenia: 2022-2032
- Negative symptom cases of schizophrenia: 2022-2032
- Disease definition, methods, and sources used
- Diagnosed lifetime prevalent cases with cognitive impairment: 2022-2032
- Number of lifetime diagnosed and drug-treated prevalent cases of schizophrenia in the major pharmaceutical markets: 2022-2032
- Key findings
- Current Treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for schizophrenia
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for schizophrenia
- Current treatments used for schizophrenia
- Market events impacting the use of key current therapies for schizophrenia
- Timeline of launches of key drugs for schizophrenia in the United States
- Atypical antipsychotics
- Impact of receptor binding on efficacy / safety profile of select atypical antipsychotics
- Advantages and disadvantages of oral aripiprazole
- Advantages and disadvantages of aripiprazole one-month depot
- Expert insight: aripiprazole
- Advantages and disadvantages of aripiprazole lauroxil
- Expert insight: aripiprazole lauroxil
- Advantages and disadvantages of oral asenapine
- Advantages and disadvantages of asenapine transdermal patch
- Expert insight: asenapine
- Advantages and disadvantages of oral blonanserin
- Advantages and disadvantages of blonanserin transdermal patch
- Advantages and disadvantages of brexpiprazole
- Ongoing clinical development of brexpiprazole
- Expert insight: brexpiprazole
- Advantages and disadvantages of cariprazine
- Ongoing clinical development of cariprazine
- Expert insight: cariprazine
- Advantages and disadvantages of clozapine
- Expert insight: clozapine
- Advantages and disadvantages of iloperidone
- Advantages and disadvantages of lumateperone
- Expert insight: lumateperone
- Advantages and disadvantages of lurasidone
- Expert insight: lurasidone
- Advantages and disadvantages of oral olanzapine
- Advantages and disadvantages of Lybalvi
- Advantages and disadvantages of olanzapine pamoate
- Expert insight: olanzapine
- Advantages and disadvantages of oral paliperidone
- Advantages and disadvantages of paliperidone palmitate one-month depot
- Advantages and disadvantages of paliperidone palmitate three-month and six-month depots
- Expert insight: paliperidone
- Advantages and disadvantages of quetiapine
- Expert insight: quetiapine
- Advantages and disadvantages of oral risperidone
- Advantages and disadvantages of risperidone microspheres: Risperdal Consta
- Advantages and disadvantages of risperidone one-month depot: Perseris
- Advantages and disadvantages of risperidone one-month depot: risperidone ISM (Okedi)
- Expert insight: risperidone
- Advantages and disadvantages of ziprasidone
- Advantages and disadvantages of typical antipsychotics
- Expert insight: typical antipsychotics
- Advantages and disadvantages of dexmedetomidine sublingual film
- Expert insight: dexmedetomidine sublingual film
- Medical practice
- Overview
- Factors influencing drug selection in schizophrenia
- Treatment decision tree for schizophrenia: United States
- Treatment decision tree for schizophrenia: Europe
- Treatment decision tree for schizophrenia: Japan
- Major-market treatment decision tree for CIAS
- Major-market treatment decision tree for the side effects of antipsychotics in schizophrenia
- Major-market treatment decision tree for the comorbid symptoms of schizophrenia
- Key findings
- Unmet Need Overview
- Current and future attainment of unmet needs in schizophrenia
- Top unmet needs in schizophrenia: current and future attainment
- Expert insight: unmet need in schizophrenia
- Drug Pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging Therapies
- Key findings
- Key emerging therapies
- Key therapies in development for schizophrenia
- Estimated launch dates of key emerging therapies for the treatment of schizophrenia
- Pimavanserin profile
- Analysis of the clinical development program for pimavanserin
- Expert insight: pimavanserin
- Expectations for launch and sales opportunity of pimavanserin in schizophrenia
- Likely uses of pimavanserin for the treatment of schizophrenia
- Brilaroxazine profile
- Analysis of the clinical development program for brilaroxazine
- Expert insight: brilaroxazine
- Expectations for launch and sales opportunity of brilaroxazine in schizophrenia
- Risperidone oral weekly (LYN-005) profile
- Analysis of the clinical development program for risperidone oral weekly (LYN-005)
- Expectations for launch and sales opportunity of risperidone oral weekly (LYN-005) in schizophrenia
- TEV-44749
- TEV-44749 profile
- Analysis of the clinical development program for TEV-44749
- Expectations for launch and sales opportunity of TEV-44749 in schizophrenia
- Paliperidone palmitate ER injectable suspension (LY03010)
- Paliperidone palmitate ER injectable suspension (LY0310) profile
- Analysis of the clinical development program for paliperidone palmitate ER injectable suspension (LY03010)
- Expectations for launch and sales opportunity of paliperidone palmitate ER injectable suspension (LY03010) in schizophrenia
- Iclepertin (BI 425809) profile
- Analysis of the clinical development program for iclepertin (BI 425809)
- Expert insight: iclepertin (BI 425809)
- Expectations for launch and sales opportunity of iclepertin (BI 425809) in schizophrenia
- Likely uses of iclepertin (BI 425809) for the treatment of schizophrenia
- Ulotaront (SEP-363856) profile
- Analysis of the clinical development program for ulotaront (SEP-363856)
- Expert insight: ulotaront (SEP-363856)
- Expectations for launch and sales opportunity of ulotaront (SEP-363856) in schizophrenia
- Roluperidone (MIN-101) profile
- Analysis of the clinical development program for roluperidone (MIN-101)
- Expert insight: roluperidone (MIN-101)
- Expectations for launch and sales opportunity of roluperidone (MIN-101) in schizophrenia
- KarXT profile
- Analysis of the clinical development program for KarXT
- Expert insight: KarXT
- Expectations for launch and sales opportunity of KarXT in schizophrenia
- Likely uses of KarXT for the treatment of schizophrenia
- Evenamide profile
- Analysis of the clinical development program for evenamide
- Expert insight: evenamide
- Expectations for launch and sales opportunity of evenamide in schizophrenia
- Valbenazine profile
- Analysis of the clinical development program for valbenazine
- Expert insight: valbenazine
- Expectations for launch and sales opportunity of valbenazine in schizophrenia
- Early-phase pipeline analysis
- Select compounds in early-phase development for schizophrenia
- Key findings
- Access & Reimbursement Overview
- Region-specific reimbursement practices
- Key market access considerations in schizophrenia: United States
- General reimbursement environment: United States
- Key market access considerations in schizophrenia: EU5
- General reimbursement environment: EU5
- Key market access considerations in schizophrenia: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Bibliography
- Key Updates
Shayan Chakraborty is a senior healthcare research and data analyst on the CNS/Ophthalmology Disorders team at Clarivate. In this role, he oversees the team’s syndicated research stream in neurology, with a core focus on migraine. He has several years of experience working in the pharmaceutical industry providing analytical support in various therapy areas, including oncology, vaccines, specialty pharma, and rare diseases.
Prior to joining Clarivate, he was an assistant manager at WNS Global Services, where he was responsible for providing analytical and forecasting support to Global Vaccine Business Insight partners for early-phase products. He holds a bachelor’s degree in biotechnology from West Bengal University of Technology and a master’s degree in biotechnology and biochemical engineering from the Indian Institute of Technology, Kharagpur. Currently, he is pursuing India’s first full-time online bachelor’s degree in data science and programming from the Indian Institute of Technology, Madras.
Himanshu Jain, M.S.(Pharm.), Senior Manager, CNS and Ophthalmology. He has authored content for psychiatry and ophthalmology indications, including forecasting markets for schizophrenia, depression, and dry eye disease. He has about 15 years of experience working in market research and consulting firms. He earned his master’s degree in Pharmacology & Toxicology from the National Institute of Pharmaceutical Education and Research and holds an Executive Post-Graduate Diploma in International Business from the Indian Institute of Foreign Trade.
Riya Kanakhara, B.Tech., Associate Healthcare Research & Data Analyst, CNS and Ophthalmology. Ms. Kanakhara has substantial experience in market research and has produced competitive intelligence reports in multiple therapy areas, including oncology, ophthalmology, neurology, and psychiatry. She has also prepared post-conference reports for conferences such as the American Academy of Neurology. She holds a bachelor’s degree in biotechnology from Amity University in India.
